Combining Gemcitabine with Flutamide for Pancreatic Cancer
Author Information
Author(s): Corrie P, Mayer A, Shaw J, D'Ath S, Blagden S, Blesing C, Price P, Warner N
Primary Institution: Oncology Centre, Addenbrooke's Hospital, Cambridge
Hypothesis
Can the combination of gemcitabine and flutamide improve treatment outcomes in patients with advanced pancreatic cancer?
Conclusion
The combination of gemcitabine and flutamide is well tolerated and shows a response rate similar to gemcitabine alone.
Supporting Evidence
- The response rate was 15%, with four partial responses recorded.
- Median survival was 6 months, with 22% of patients alive at 1 year.
- Most toxicities were mild, with only nine cycles associated with grade 3 toxicity.
Takeaway
Doctors tested a new medicine combination to help people with a tough kind of cancer, and it worked okay without making them too sick.
Methodology
Patients received gemcitabine and flutamide, with assessments of toxicity and tumor response after several treatment cycles.
Potential Biases
Potential bias due to the lack of randomization and small sample size.
Limitations
The study had a small sample size and did not include formal quality of life assessments.
Participant Demographics
All participants had histologically confirmed pancreatic adenocarcinoma, with 24 presenting with advanced disease.
Statistical Information
P-Value
0.046
Statistical Significance
p=0.046
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website